Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
May 18, 2016 — Data to be Presented at the 2016 ASCO Annual Meeting — — Company to Discuss Results with Regulators after Additional Follow Up — BOSTON, May 18, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that interim ...
PDF
May 10, 2016 BOSTON, May 10, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities. "We have solid momentum in each of our cell and gene therapy programs, with the potent...
PDF
Apr 18, 2016 BOSTON, April 18, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The...
PDF
Mar 31, 2016 BOSTON, March 31, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2nd Annual Immuno-Oncology Summit on Thursday, April 7th, 2016 at 9:35 a.m. ET. The conference is being held at the B...
PDF
Mar 9, 2016 BOSTON, March 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of an article describing the use of Sleeping Beauty non-viral gene transfer technology to modify T cells for the targeting of neoantigens present within ...
PDF
Feb 24, 2016 BOSTON, Feb. 24, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter ended December 31, 2015, and provided an update on the Company's recent activities. "We look forward to a number of important milestones throughout 2016 across our gene and cel...
PDF
Feb 24, 2016 BOSTON, Feb. 24, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that, following the successful completion of the initial dose cohort, the first patient has been dosed at the succeeding dose level in the Company's ongoing multicenter Phase 1 st...
PDF
Feb 23, 2016 BOSTON, Feb. 23, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of a study in Scientific Reports, a journal of the Nature Publishing Group, describing the genetic editing of human leukocyte antigen (HLA) in hematopoiet...
PDF
Feb 9, 2016 BOSTON, Feb. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in pa...
PDF
Feb 2, 2016 BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9th, 2016 at 1:00 p.m. ET. The conference is being held at the Waldo...
PDF
Page:
1
... NextLast